Cannabis Law and Access in Spain

Spain's cannabis framework: not legalised, not quite prohibited

Forty-seven million people live under a cannabis legal framework that is, frankly, one of the more internally contradictory in Europe. Spain has never fully legalised cannabis, never passed a national law permitting adult-use sale, and yet hosts a dense network of members-only cannabis associations that have operated relatively openly since the early 2010s. Understanding why requires separating three layers of Spanish law that mostly do not talk to each other: the criminal code, the administrative (public order) law, and a set of regional court decisions that have done a lot of heavy lifting in the interim.

For Australian readers, a note upfront: none of this is Australian law. Spain's framework does not affect what is legal or accessible here. If you are thinking about cannabis access in Australia, the relevant instruments are the Therapeutic Goods (Poisons Standard , Cannabis and Cannabis Resin) Order, the TGA's Special Access Scheme, and the Authorised Prescriber pathway under Schedule 8 of the Poisons Standard. Very different architecture. I'll come back to that comparison briefly at the end.

The criminal law position

Spain's Código Penal (Organic Law 10/1995, as amended) does not criminalise personal consumption of cannabis. Possession and use in a private space is not a criminal offence. Trafficking , supply, sale, cultivation for commercial distribution , remains a criminal offence, carrying custodial sentences that escalate based on quantity and aggravating factors.

The critical distinction the Spanish courts have drawn, repeatedly and consistently, is between autoconsumo (self-supply, private use) and any act with a "social diffusion" character; i.e., something that makes cannabis available to others beyond a tightly defined private circle. That line has been contested in roughly a hundred regional court cases over two decades. The outcome of all that litigation is a doctrine, not a statute.

The administrative layer and the cannabis clubs

Public consumption, in a street, park, or any publicly visible space, is an administrative infraction under the Ley Orgánica de Seguridad Ciudadana (Organic Law 4/2015, commonly called the "Gag Law"). Fines range from €601 to €30,000 depending on circumstances. This is a civil penalty, not a criminal charge, but it is enforced.

Cannabis social clubs (asociaciones cannábicas) emerged from the gap between these two positions. Spanish civil association law allows adults to form private non-profit associations for lawful purposes. A series of Basque Country court decisions between roughly 2008 and 2015 found that a tightly structured members-only club; closed membership, no advertising, no public-facing sale, consumption on premises only, cultivation proportionate to member needs, could fall within the autoconsumo doctrine. Members collectively cultivate and collectively consume; no "social diffusion" to non-members occurs.

The Basque regional parliament went further and passed its own regulatory framework for clubs in 2017, the first sub-national cannabis regulation in Spain. Catalonia moved toward similar regulation but had its own framework struck down by the Constitutional Court in 2017 on the grounds that drug policy is a national competency. So the clubs outside the Basque Country continue to operate in a grey zone defined by court doctrine rather than statute.

I'll admit I got this wrong for years, I assumed the clubs were formally licensed in the way a pharmacy dispensary might be. They are not. Most operate under standard civil association registration, and their legal tolerance rests almost entirely on how prosecutors and courts interpret the autoconsumo doctrine case-by-case. That is a fragile basis for anything.

Pharmaceutical and medical access

Spain has an approved pharmaceutical-grade cannabis product registered through the Spanish Agency of Medicines and Medical Devices (AEMPS, the rough Spanish equivalent of the TGA). A cannabidiol-based oral solution has held regulatory approval for specific indications since 2019, under the same EU-wide process that approved it across member states. That product is prescription-only, dispensed through hospital pharmacies, and subject to strict supply chain controls. It is not the same as club-distributed cannabis.

Separately, Spain permits the use of THC-containing preparations under its uso compasivo (compassionate use) framework; analogous in broad structure to Australia's Special Access Scheme, though the procedural details differ considerably. Individual hospital physicians can apply to AEMPS for authorisation to use a non-approved medicine for a named patient. It is not a general access pathway.

Industrial hemp and CBD products

EU regulation governs hemp cultivation. Spain permits the cultivation of hemp varieties listed on the EU Common Catalogue, provided THC content stays at or below 0.3% (the EU threshold, tightened from 0.2% in 2023). Hemp seed, fibre and certified extracts from compliant cultivars are legal agricultural commodities.

CBD products sit in a less tidy position. The European Food Safety Authority (EFSA) placed cannabidiol under the Novel Food Regulation in 2019, meaning any food supplement or ingestible product containing CBD technically requires a Novel Food authorisation before lawful sale. Spain has largely followed the EU-level position, though enforcement across member states has been wildly inconsistent. Shops selling CBD oils, topicals and related products have continued to trade in Spanish cities; the regulatory picture for those products remains unsettled at the EU level as of 2024.

This is where the chemistry becomes relevant, briefly. Products derived from hemp can contain a range of cannabinoids beyond CBD, CBG, CBN, trace cannabinoids, and an array of terpenes that affect the character of a full-plant extract. Whether a product qualifies as full-spectrum, broad-spectrum, or an isolate matters both to its regulatory classification and to how the extract is characterised under Novel Food rules.

Where Spain sits in European context

Germany's move to partial adult-use legalisation under the Konsumcannabisgesetz (effective April 2024) has sharpened attention on Spain's framework by comparison. Germany's approach is statute-based, nationally applied, and explicitly permits possession of defined quantities and home cultivation for adults. Spain's tolerance remains court-doctrine-based and geographically uneven. In my view, Spain's current position is structurally unstable, not because the clubs are actively being shut down (they mostly are not), but because a law that exists only in judicial interpretation can be redrawn by the next set of court decisions or by a government with a different appetite for enforcement.

The Spanish Congress has seen multiple cannabis reform bills tabled and stalled over the last decade. None has passed as of mid-2025. The political coalition arithmetic has not produced a majority for national reform.

The Australian comparison

I spent part of last Sunday sorting through some vintage survey maps I picked up at a Braddon market stall; totally unrelated, but it reminded me how much depends on the underlying structure of a framework, not just what it permits on the surface. Spain's cannabis tolerance is all surface. Australia's medicinal cannabis regime, by contrast, is densely documented: Schedule 4 and Schedule 8 classifications under the Poisons Standard, product registration on the ARTG, mandatory Good Manufacturing Practice standards for cultivation and manufacture, and two formal access pathways (the Special Access Scheme and the Authorised Prescriber scheme). It is more restrictive in some respects and more clearly bounded in others.

Australian residents cannot import cannabis products from Spain, cannot rely on Spain's legal framework here, and, if prescribed medicinal cannabis in Australia, receive a product that has met TGA quality and manufacturing requirements. The regulatory floors are very different.

Spain's framework is interesting as a case study in how criminal law tolerance and civil law registration can coexist, imperfectly, for years. Whether it represents a stable or desirable model is a separate question; and one that European policymakers are actively arguing about right now.

Sources

• Spain Drug Report 2024, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Cannabis Medicinal, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
• Access to unapproved therapeutic goods; Therapeutic Goods Administration (TGA)
• Cannabidiol (CBD) as a Novel Food, European Food Safety Authority (EFSA)

, Marcus Hale, Regulatory researcher, TGA & access law